Sasak
Anthony Leonard Sasak, Arlington Heights, IL US
Patent application number | Description | Published |
---|---|---|
20140307746 | Method and Apparatus for Providing Timing Analysis for Packet Streams Over Packet Carriers - A network device such as a router or switch, in one embodiment, includes a timing analyzer which is capable of providing timing analysis over one or more network circuits. The timing analyzer, in one aspect, receives a data packet traveling across a circuit emulation service (“CES”) circuit such as T1 or E1 circuit. Upon obtaining an arrival timestamp associated with the data packet, the arrival timestamp is stored in a timestamp buffer in accordance with a first-in first-out (“FIFO”) storage sequence. After identifying the oldest arrival timestamp in the timestamp buffer, an offset is generated based on the result of comparison between the arrival timestamp and the oldest timestamp. The timing analyzer can also be configured to generate timing reports on-demand based on generated offset(s). | 10-16-2014 |
Vodek Sasak, Northborough, MA US
Patent application number | Description | Published |
---|---|---|
20140148404 | COMPOSITION AND USES OF GALECTIN ANTAGONISTS - The present invention is directed to methods and compositions for augmenting treatment of cancers and other proliferative disorders. In particular embodiments, the invention combines the administration of an agent that inhibits the anti-apoptotic activity of galectin-3 (e.g., a “galectin-3 inhibitor”) so as to potentiate the toxicity of a chemotherapeutic agent. In certain preferred embodiments, the conjoint therapies of the present invention can be used to improve the efficacy of those chemotherapeutic agents whose cytotoxicity is influenced by the status of an anti-apoptotic Bcl-2 protein for the treated cell. For instance, galectin-3 inhibitors can be administered in combination with a chemotherapeutic agent that interferes with DNA replication fidelity or cell-cycle progression of cells undergoing unwanted proliferation. | 05-29-2014 |
Vodek Sasak, Belmont, MA US
Patent application number | Description | Published |
---|---|---|
20150133399 | COMPOSITION AND USES OF GALECTIN ANTAGONIST - The present invention is directed to methods and compositions for augmenting treatment of cancers and other proliferative disorders. In particular embodiments, the invention combines the administration of an agent that inhibits the anti-apoptotic activity of galectin-3 (e.g., a “galectin-3 inhibitor”) so as to potentiate the toxicity of a chemotherapeutic agent. In certain preferred embodiments, the conjoint therapies of the present invention can be used to improve the efficacy of those chemotherapeutic agents whose cytotoxicity is influenced by the status of an anti-apoptotic Bcl-2 protein for the treated cell. For instance, galectin-3 inhibitors can be administered in combination with a chemotherapeutic agent that interferes with DNA replication fidelity or cell-cycle progression of cells undergoing unwanted proliferation. | 05-14-2015 |